# Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).

> **NCT03634826** · — · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Carcinoma
- Lung Cancer
- NSCLC
- Lung Neoplasm

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03634826
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-15
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-01-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03634826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03634826, "Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03634826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*